Elopak Q2 2025 presentation: Americas growth drives stable performance amid expansion

Elopak ASA reported stable Q2 2025 results, with revenue up 0.4% to €289.6 million (2.4% organic constant currency) and EBITDA improving 2.1% to €44.7 million, yielding a 15.4% margin. This was largely driven by robust 7.4% growth in the Americas, fueled by the new U.S. plant nearing break-even, while the larger EMEA region saw flat revenue and margin contraction. Significant investments in the U.S. facility contributed to increased net financial debt of €302 million and a declining Return on Capital Employed (ROCE) to 14.6%; however, the company declared a €0.03 dividend, signaling confidence in its strategic focus on sustainable packaging and U.S. market expansion despite an increasingly competitive environment.

Analysis

Elopak ASA's Q2 2025 results reveal a company in a strategic transition, characterized by a stark divergence in regional performance. While headline revenue grew a marginal 0.4% to €289.6 million, constant currency organic growth of 2.4% indicates healthier underlying demand, driven almost entirely by the Americas region which posted an impressive 14% organic growth. This contrasts sharply with the core EMEA segment, representing 73% of revenue, which remained flat and experienced EBITDA margin contraction to 15.7% from 16.4% due to an unfavorable sales mix and higher R&D spending. The company's significant investment in its new U.S. manufacturing facility is pressuring key financial metrics; net debt has risen to €302 million and Return on Capital Employed (ROCE) has declined to 14.6% from 17.7% a year prior. However, this U.S. plant is now approaching break-even, and its adjusted EBITDA margin of 23.6% in the Americas highlights its long-term profit potential. Management's confidence is signaled by the declaration of a €0.03 dividend, despite a 50% drop in earnings per share to €0.03, suggesting a commitment to shareholder returns while navigating this capital-intensive growth phase.

Key Decisions for Investors

• Investors should closely monitor the U.S. plant's progress toward its year-end 2025 full ramp-up target, as the successful execution of this initiative is critical to reversing the declining ROCE and validating the company's growth strategy.
• The stagnant growth and margin compression in the core EMEA region presents a significant risk; a continued lack of improvement in this largest segment could undermine the strong performance from the Americas.
• Given the mixed profile of strong growth in one region offset by weakness in another and pressure on profitability metrics, it may be prudent to hold existing positions while awaiting clearer signs that the U.S. investment is translating into improved consolidated earnings.